News

Investing Snacks1d
Vertex Eyes Growth With CF and Pain Drug Innovations
PGIM Jennison Health Sciences Fund’s Q1 2025 letter highlights mixed sector returns, with Vertex Pharmaceuticals in focus.
VRTX price slides 40% as Vertex Protocol phases out native token, abandons Arbitrum
The hybrid decentralized exchange has confirmed that it will shut down its platform on Arbitrum and move to Kraken-backed L2 ...
Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)?
PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...